Aevi (GNMX) PT Lowered to $0.20 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 hits record high as rate-hike worries ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Pre-Open Stock Movers 01/03: (OHRP) (CELG) (DBVT) Higher; (AAPL) (LITE) (BMY) Lower (more...)
January 3, 2019 9:22 AM ESTPre-Open Movers
Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) 73.6% HIGHER; announced today that it has entered into a definitive merger agreement with NeuBase Therapeutics, Inc., under which the stockholders of NeuBase would become the majority holders of the combined company. The proposed merger will create a public company focused on advancing NeuBases peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL) technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations.
Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) 70.4% LOWER;... More
JMP Securities Downgrades Aevi (GNMX) to Market Perform
January 3, 2019 5:40 AM ESTJMP Securities analyst Jason Butler downgraded Aevi (NASDAQ: GNMX) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Aevi click here. For more ratings news on Aevi click here.
Shares of Aevi closed at $0.77 yesterday.
... MoreAfter-Hours Movers 01/02: (GNMX) (LITE) (AAPL) Lower (more...)
January 2, 2019 6:04 PM ESTToday's After-Hours Movers
Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) 70.4% LOWER; announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 400 mg BID) in children aged 6 17 with Attention Deficit Hyperactivity Disorder (ADHD) with an mGluR copy number variant... More
Aevi Genomic Medicine (GNMX) Reports ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD 'Did Not Achieve Statistical Significance on Primary Endpoint'
January 2, 2019 4:36 PM ESTAevi Genomic Medicine, Inc. (NASDAQ: GNMX) ("the Company") today announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 400 mg BID) in children aged 6 17 with Attention Deficit Hyperactivity Disorder (ADHD) with an mGluR copy number variant (Part A) or without an mGluR copy number variant (Part B), did not achieve statistical significance on... More
Aevi Genomic Medicine (GNMX) halted, news pending
January 2, 2019 4:27 PM ESTAevi Genomic Medicine (NASDAQ: GNMX) halted, news pending
... More